Press release
Pharmacogenomics Market Size to Reach USD 8.87 Billion by 2033 as Precision Medicine, Genomic Testing and Personalized Drug Therapy Support Growth
Pharmacogenomics Market Size
Download Free Sample PDF of the Report: https://www.datamintelligence.com/download-sample/pharmacogenomics-market?akash
Pharmacogenomics Market Recent Developments
July 2026 - Tempus AI: Tempus announced the national launch of its OneOme pharmacogenomics testing solution in the United States. The service offers single-gene and multi-gene testing to provide information related to medication safety, dosing and toxicity risk.
US Recent Developments
January 2026 - CMS: The U.S. Centers for Medicare & Medicaid Services updated its pharmacogenomics testing billing article as part of the annual coding changes, reflecting continued administrative development around pharmacogenomic testing services.
July 2026 - Tempus AI: Tempus expanded national availability of OneOme PGx testing, integrating pharmacogenomic information into its broader precision-medicine offering.
Japan Recent Developments
March 2026 - NTT Precision Medicine: NTT Precision Medicine announced Genovision PGx, a genetic testing service designed to provide information on genetic tendencies related to medication response and adverse-effect risk. The service began in April.
July 2026 - AMED: Japan's AMED selected research projects under its genomic drug-discovery program, including work on building a Japanese pharmacogenomics platform based on measured functional data from low-frequency variants and supporting clinical implementation.
August 2026 - NTT Precision Medicine: The company announced participation in a clinical pharmacology symposium focused on the practical implementation of psychiatric pharmacogenomics, including research conducted with Chiba University Hospital.
Mergers and Acquisitions
July 2026 - Tempus AI: Tempus entered into an agreement to acquire Personalis, strengthening its precision-oncology capabilities and expanding its genomic data and testing portfolio. The transaction complements Tempus's broader precision-medicine activities, including its pharmacogenomics offering.
September 2026 - Gene S Dx: Gene S Dx acquired the Gene S business and its Rosa pharmacogenomics platform. The platform combines genetic sequencing with software for pharmacogenomic analysis, adding another specialized PGx capability to the precision-medicine field.
Pharmacogenomics Market Segmentation
By Product and Service Type: Kits & Reagents, Instruments, and Software & Services. Kits and reagents support laboratory testing, while software and services assist with interpretation and clinical use.
By Technology: DNA Sequencing, Polymerase Chain Reaction, Microarray, Electrophoresis, Mass Spectrometry and Others. PCR is a key technology segment, a share of approximately 32% of its stated segment value.
By Application: Drug Discovery, Personalized Medicine, Clinical Research and Others. Personalized medicine is closely linked with pharmacogenomics because genetic information can help inform medication selection and dosing.
By Disease Area: Oncology, Cardiovascular Disorders, Neurological Diseases, Infectious Diseases, Mental Health and Others. Oncology is an important application area because genetic differences can influence treatment response and toxicity.
Speak to Our Analyst and Get Customization in the Report as per Your Requirements: https://www.datamintelligence.com/customize/pharmacogenomics-market?akash
Key Players
Abbott Laboratories
Agilent Technologies Inc.
Illumina
QIAGEN
Thermo Fisher Scientific Inc.
Abbott Laboratories: Abbott operates across diagnostics and healthcare technologies, with testing capabilities supporting clinical decision-making and personalized healthcare applications.
Illumina: Illumina develops sequencing technologies used to analyze genetic information. Its sequencing platforms support genomic research and applications connected with precision medicine.
Pharmacogenomics Market Regional Analysis
United States
The United States remains an important market due to its established genomic research infrastructure, pharmaceutical industry and clinical testing capabilities. The FDA maintains extensive pharmacogenomic resources, and a 2026 review found that about 29% of FDA-listed pharmacogenomic drug labels recommend or require genetic testing, highlighting the clinical role of PGx information in medication decisions.
Japan
Japan is strengthening its genomic medicine infrastructure through government programs, research funding and clinical testing services. In a study of Japanese drug labels, 14 of 52 (26.9%) labels with pharmacogenomic information were classified as "Testing Required," and all 14 were covered by Japan's National Health Insurance.
Conclusion
The pharmacogenomics market growth is being supported by increasing interest in precision medicine, genomic testing and treatment decisions informed by genetic differences. Continued development of sequencing, PCR, multi-gene panels and clinical interpretation tools is expanding the role of pharmacogenomic information in healthcare and drug development.
Unlock Complete Market Intelligence with the Full Report: https://www.datamintelligence.com/buy-now-page?report=pharmacogenomics-market?akash
FAQs
1. What is driving the pharmacogenomics market?
2. What are the major pharmacogenomics market segments?
3. What is the pharmacogenomics market forecast?
Contact Us:
Sai Kiran
Business Development Manager
DataM Intelligence 4market Research LLP
6th Floor, M2 Tech Hub, Lalitha Nagar, Habsiguda,
Secunderabad, Hyderabad, Telangana 500039
USA: +1 877-441-4866
Email: Sai.k@datamintelligence.com
About Us :
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Pharmacogenomics Market Size to Reach USD 8.87 Billion by 2033 as Precision Medicine, Genomic Testing and Personalized Drug Therapy Support Growth here
News-ID: 4643550 • Views: …
More Releases from DataM intelligence 4 Market Research LLP
AI in Elderly Care Market Size to Reach USD 36.64 Billion by 2035 | As AI Compan …
According to DataM Intelligence, The global AI in Elderly Care Market was valued at US$ 6.47 billion in 2025 and is projected to reach US$ 36.64 billion by 2035, expanding at a 22.12% CAGR during 2026-2035. AI is rapidly transforming elderly care through real-time health monitoring, intelligent fall detection, predictive risk analysis, AI companions and automated care coordination.
Rising caregiver shortages and the growing preference for aging in place are…
Industrial AI Copilots Market Size Set to Reach USD 24.21 Billion by 2035 | As S …
According to DataM Intelligence, The Global Industrial AI Copilots Market reached US$ 2.36 billion in 2025 and is projected to reach US$ 24.21 billion by 2035, expanding at a CAGR of 26.20% during 2026 To 2035. The growth outlook is being driven by the increasing integration of generative AI, industrial automation, predictive maintenance, digital twins and real-time operational intelligence across manufacturing and industrial environments.
Demand is also supported by the…
Email Encryption Market Size Set to Reach USD 41.41 Billion by 2033 | As Zero Tr …
According to DataM Intelligence, The Global Email Encryption Market Size reached US$ 7.66 billion in 2025 and is projected to reach US$ 41.41 billion by 2033, expanding at a CAGR of 23.5% during 2026-2033. Email encryption protects message content from unauthorized access and supports secure communication when organizations exchange sensitive information.
Demand is being driven by increasing phishing, data-loss, privacy and compliance risks, alongside the migration of enterprise email to…
SiC Wafer Polishing Market Size Set to Reach USD 7,145.0 Billion by 2033 | As 20 …
According to DataM Intelligence, The SiC Wafer Polishing Market was valued at US$ 566.0 billion in 2025 and, based on the supplied forecast, is projected to reach approximately US$ 7,145.0 billion by 2033, expanding at a reported CAGR of 37.3% during 2026 To 2033. The growth outlook is being driven by increasing demand for silicon carbide power semiconductors, electric vehicles, renewable energy systems, high voltage power electronics and advanced semiconductor…
More Releases for Pharmacogenomics
Pharmacogenomics - Top Companies Regional and Data Analysis
Pharmacogenomics is a branch of science, which studies the role of gene over the activity of a drugs and hence helps the refreshers in predicting the response of novel as well as previously available therapies.
Get More Details with Sample PDF Copy @ https://www.theinsightpartners.com/sample/TIPRE00007564/?utm_source=OpenPR&utm_medium=10129
Major Companies operating in the Pharmacogenomics Market are:
• F. Hoffmann-la Roche Ltd
• Abbott
• Oxford Nanopore Technologies
• Thermo Fisher Scientific Inc.
• Illumina, Inc.
• QIAGEN
• Agilent Technologies, Inc.
• Myriad Genetics, Inc.
• Admera Health
Contact Us:
If you have any queries about…
Pharmacogenomics Market worth $5.8 billion by 2028
North America region is witnessing increasing investments and research activities in the field of drug discovery and development. The need for advanced therapies due to rising rate of cancer has contributed to growth of the pharmacogenomics market.
Pharmacogenomics Market [https://www.marketsandmarkets.com/Market-Reports/pharmacogenomics-market-142682251.html?utm_source=ABnewswire&utm_campaign=Paid&utm_content=Referral] in terms of revenue was estimated to be worth $3.5 billion in 2023 and is poised to reach $5.8 billion by 2028, growing at a CAGR of 10.6% from 2023 to…
Genetic Medicine: Unveiling the Power of Pharmacogenomics
Based on technology, the pharmacogenomics market is segmented into PCR, sequencing, microarray, gel electrophoresis, mass spectrometry, and others. The market for the PCR segment is subsegmented into real time PCR, standard PCR, and digital PCR. The PCR segment dominated the pharmacogenomics market in 2021 and is expected to register the highest CAGR during the forecast period.
Download Sample PDF Details at: https://www.theinsightpartners.com/sample/TIPRE00007564?utm_source=OpenPR&utm_medium=10776
The pharmacogenomics market is segmented on the basis of…
Complete PDF Guide On Pharmacogenomics [PDF]
According to our latest study on "Pharmacogenoics Market Forecast to 2028 - COVID-19 Impact and Global Analysis - by Technology, Application, and End User," the market is projected to reach US$ 14,107.80 million by 2028 from US$ 7,087.81 million in 2021; it is expected to grow at a CAGR of 10.3% from 2021 to 2028. The report highlights the key factors driving the market growth and prominent players with their…
Global Pharmacogenomics Market Size & Trends
According to a new market research report published by Global Market Estimates, the global pharmacogenomics market is projected to grow at a CAGR of 9.6% from 2023 to 2028.
The growth of the global pharmacogenomics market is driven by advancements in genomics and DNA sequencing technologies, the rising demand for personalized medicine, regulatory support from agencies like the FDA, cost-effectiveness through reduced adverse reactions, and a growing aging population with complex…
Global Pharmacogenomics Services Market Insights | 2022-2032
The Pharmacogenomics Services Market refers to the services provided by companies and laboratories that offer personalized medicine based on a patient's genetic makeup. Pharmacogenomics is the study of how an individual's genes affect their response to certain drugs, and the pharmacogenomics services market focuses on utilizing this knowledge to optimize drug therapy.
These services typically involve genetic testing to identify specific genetic variations that may impact a patient's response to certain…
